Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Pulmonary arterial hypertension is a disease characterised by pathological changes in the
pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and
pulmonary artery pressure. Right ventricular failure is the main cause of death in patients
with pulmonary arterial hypertension, and the ability of the right ventricle to adapt to the
progressive increase in pulmonary vascular resistance associated with changes to the
pulmonary vasculature in pulmonary arterial hypertension is the main determinant of a
patient's functional capacity and survival.Mesenchymal stem cells (MSCs)are a subset of adult
stem cells residing in many tissues, including bone marrow(BM), adipose tissue, umbilical
cord blood. Recent experimental findings have shown the ability of MSCs to home to damaged
tissues and to produce paracrine factors with anti-inflammatory properties, potentially
resulting in reduction of inflammation and functional recovery of the damaged tissues.It was
found that MSCs can significantly improve the pulmonary hemodynamics, lung tissue gross and
decrease the pulmonary artery pressure, middle artery thickness and right cardiac hypertrophy
by intravenous injection.